The clinical impact of early immunological responses in human HER2-positive breast cancers on responsiveness to trastuzumab-based therapy

Authors :: Darran P. O'Connor
Ailis Fagan
Arnold D.K. Hill
Colm Power
Malgorzata Milewska
William M. Gallagher
Ausra Teiserkiene
Leonie S. Young
Janice M. Walshe
Sinead Toomey
Norma O'Donovan
Alex J Eustace
Deirdre Duke
Elaine W. Kay
Joanna Fay
John Crown
M. John Kennedy
Bryan T. Hennessy
Niamh Hambly
Source :: Journal of Clinical Oncology. 34:587-587
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 587Background: ‘TCHL’ an ICORG phase-II neo-adjuvant study in HER2+ve Breast cancer (BC) assessed the impact of TCH (Docetaxel, Carboplatin, Trastuzumab) versus TCHL (Docetaxel, Carboplatin, Trastu...

Full Text Access

Tools